From GlobeNewswire:

EyePoint Pharmaceuticals, Inc. has announced new subgroup analyses from the Phase 2 DAVIO 2 clinical trial of EYP-1901, showing favorable clinical results for wet AMD patients. The data was presented at the Angiogenesis, Exudation, and Degeneration 2024 Meeting by Dr. Charles C. Wykoff and Dr. Carl Regillo. The analyses demonstrate that EYP-1901 patients showed favorable change in best corrected visual acuity (BCVA) and anatomic stability, confirming the promising Phase 2 trial results. Plans for upcoming Phase 3 trials are expected to initiate in the second half of 2024. The Phase 2 DAVIO 2 trial of EYP-1901 demonstrated statistical non-inferiority for BCVA and a favorable safety profile, with no serious adverse events related to EYP-1901. Subgroup analyses confirmed the positive topline data were driven by EYP-1901, not supplemental injections. The EYP-1901 treatment showed consistent and durable outcomes in a range of wet AMD patient types. The Phase 2 PAVIA trial in non-proliferative diabetic retinopathy (NPDR) is expected to report topline data in the second quarter of 2024. The Company anticipates the initiation of a Phase 3 trial in wet AMD in the second half of 2024. EyePoint Pharmaceuticals is committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. Our pipeline leverages our proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. Our lead product candidate, EYP-1901, is an investigational sustained delivery treatment for VEGF-mediated retinal diseases. Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. We are headquartered in Watertown, Massachusetts.



Read more: EyePoint Pharmaceuticals Announces Two Presentations of